<DOC>
	<DOCNO>NCT00744718</DOCNO>
	<brief_summary>This phase II trial investigate effect bevacizumab carboplatin patient platin resistant ovarian cancer .</brief_summary>
	<brief_title>Bevacizumab Carboplatin Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically verified epithelial ovarian cancer , primary tuba primary peritoneal cancer ( Stage IIV ) 2 . Carboplatin resistant ovarian cancer previously treat maximum three different cytostatic regimen ( single substance combination ) . 3 . Age ≥ 18 year . 4 . Performance status 02 . 5 . Measurable disease accord CA125 GCIG criterion ( Gynaecologic Cancer Intergroup ) RECIST ( Response Evaluation Criteria Solid Tumors ) ( See appendix I+II ) 6 . Adequate bonemarrow , liver kidney function coagulation parameter ( within seven day start treatment ) . 7 . ANC ≥ 1.5*109 8 . Thrombocytes ≥ 100*10^9/L 9 . Haemoglobin ( Hb ) ≥ 6 mmol/l 10 . Sebilirubin ( BR ) ≤ 1.5*ULN ( Upper Limit Normal ) 11 . Setransaminase ≤ 2.5*ULN 12 . Secreatinin ≤ 1.5*ULN 13 . Urin stix protein &lt; 2+ ( If stix show protein ≥2+ urin must measure 24 hour protein content must 1 g. ) 14 . INR ≤1.5 15 . APTT ≤ 1.5*ULN 16 . Signed informed consent form . 1 . Patients receive type experimental treatment participate clinical study le 28 day prior study . 2 . Pregnant breastfeed woman . A negative pregnancy test mandatory fertile woman . 3 . Fertile woman , wish use safe contraception ( e.g. , birth control pill , coil , gestagen deposit injection , subdermal implantation , hormonal vagina ring , transdermal deposit bandaid ) . 4 . Untreated bowel obstruction massive gastrointestinal tumor verify CT scan . 5 . Other present previous malignant disease apart curatively treated nonmelanoma skin cancer type cancer minimal risk relapse . 6 . CNSmetastases . 7 . Underlying medical disease adequately treat ( diabetes , cardiovascular disease ) . 8 . Uncontrolled hypertension ( persistent BP &gt; 150/100 despite antihypertensive treatment ) . 9 . Surgery incl . open biopsy le 4 week expect first dose Bevacizumab . 10 . Patients nonhealing wound fracture . 11 . Previous cerebrovascular attack ( TVA ) , transient ischaemic attack ( TIA ) subarachnoidal bleeding ( SAH ) within last six month . 12 . Thromboembolic haemorrhagic disease anamnesis . 13 . Clinically significant cardiovascular disease include Myocardial infarction unstable angina le 6 month prior treatment New York heart Association NYHA class ≥ 2 Poorly control cardial arrythmia despite medical treatment Peripheral vascular disease , grade 3 . 14 . Present previous chronical use Aspirin ( less 10 day start treatment ) Aspirin &gt; 325 mg daily . 15 . Present recent use full dose oral parenteral anticoagulant thrombolytic medicine . 16 . Preexisting neuropathy , sensoric motoric ≥ grade 2 . 17 . Decreased hearing . 18 . Bleeding tumor . 19 . Hypersensitivity active substance one substance contain protocol drug . 20 . Hypersensitivity product ovarian cell ( CHO ) Chinese hamster recombinant humanize antibody .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>